Illumina Stock News

On CNBC’s “ Halftime Report Final Trades ,” Liz Young of BNY Mellon Investment Management chose iShares MSCI United Kingdom ETF (NYSEARCA: EWU), saying that the opportunities in Europe were “insulated from Fed rate hikes, and you get a nice dividend yield while you’re in.” Amy Raskin of Chevy Chase Trust said Illumina, Inc. (NASDAQ: … Full story available on Benzinga.com

The "Halftime Report" traders give their top picks to watch for the second half.

Illumina, Inc. (NASDAQ:ILMN) was last seen down 0.4% at $313.90 and earlier hit its lowest level in over a year, extending its year-to-date deficit to 17%.

The C2intelligence Platform enables custom, cost-effective, efficient, automatic, and globally accessible cancer data management and real-time monitoring. SAN ANTONIO , Feb. 24, 2022 /PRNewswire/ -- Based on a recent industry analysis, Frost & Sullivan recognizes C2i Genomics with the 2022 North American Digital Cancer Monitoring Platform Technology Innovation Leadership Award. The company improves cancer monitoring through its globally accessible digital cancer monitoring system. Based on the next-generation sequencing (NGS) technology, the system allows whole genome sequencing (WGS) to occur quickly prior to analyzing large volumes of data generated. WGS, unlike medical scans or regular blood tests, provides insights and details at the genomic level. It detects richer genomic signatures from circulating tumor DNA (ctDNA) and covers all genes, expanding the scope to provide information based on larger sequenced regions. C2i Genomics C2i Genomics'' scalable software-as-a-service (SaaS) solution analyzes the WGS for high-precision, personalized cancer management to meet existing cancer monitoring shortcomings.

WASHINGTON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Epigenetics Market finds that increasing cancer rates may further expediting market growth. Primarily driven by increasing research activity and funding for Epigenetics, the total Global Epigenetics Market is estimated to reach USD 3.0 Billion by 2028. The market stood at a revenue of USD 0.8 Billion in the year 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 13.1%. Furthermore, the increasing personalized medication, and target therapy are also anticipated to augment the growth of the Global Epigenetics Market, states Vantage Market Research, in a report, titled " Epigenetics Market by Product (Instruments, Reagents & Kits, Others), by Application (Oncology, Autoimmune Diseases, Metabolic Diseases, CNS/Pain Diseases), by Technology (Methylation, Acetylation, Phosphorylation, Other Technologies), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Shopify Inc. (SHOP), and Intercontinental Exchange, Inc. (ICE).

DUBLIN , Feb. 18, 2022 /PRNewswire/ -- The "Global Laboratory Consumables Market 2021" report has been added to ResearchAndMarkets.com''s offering. The Global Laboratory Consumables Market report is designed for general management, product managers and marketing executives in the laboratory consumables industry. For them, it provides up-to-date market data about those technologies in their areas of interest. and related markets. Information on specific segments or the whole industry can be used to evaluate markets, the competitive landscape, or identify opportunities and acquisition targets. A strategy for the consumables market must involve geographic market composition, market growth rate, and new competitors. This report saves time by providing comprehensive data in an easily readable format. Companies covered in the report include: Agilent Beckman Coulter Bio-Rad Danaher Eppendorf GE Healthcare Hitachi High Technologies Illumina Lonza … Full story available on Benzinga.com

On Feb. 15, institutional investment managers with over $100m AUM disclosed their 2021-end positions. Check my list of some of the best-performing hedge funds.

Illumina's (ILMN) GRAIL Galleri MCED test detects more than 50 types of cancer and can predict the origin of the cancer signal with high accuracy across multiple cancer types.

Panel Session will Explore How to Use CDMC to Build Pragmatic Solutions for Governing Data in the Cloud Securiti , the leader in multicloud data privacy, protection and governance, today announced it will host an expert panel webinar with the EDM Council on how to Innovate Safely in Multicloud with the CDMC Framework for Data Security, Privacy and Governance . WHO : Norm Fjeldheim, Former CIO, Illumina and Qualcomm Amit Bhardwaj, CISO, Lumentum Oleg Aspis, Managing Director-Office of the Chief Data Officer, TIAA Mike Meriton, Co-Founder & COO, EDM Council Srinivas Avasarala, Vice President, Product Management, Securiti WHAT : Data is becoming the lifeblood of organizations. While it presents great opportunities for developing new products and increasing revenue, it also … Full story available on Benzinga.com

Las Vegas, USA, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Molecular Diagnostics Market is Expected to Grow at a Substantial CAGR of 9.21% and is Contemplated to Reach USD 16.12 Billion by 2026, Estimates DelveInsight Molecular Diagnostics Market is contemplated to witness huge demand in the upcoming years due to rising infectious diseases and their diagnosis, the presence of global as well as regional manufacturers active in developing the Molecular Diagnostic products such as Qiagen, Roche, Molbio Diagnostics Pvt. Ltd., among others. Also, improving healthcare infrastructure, government initiatives in raising awareness regarding molecular diagnosis will contribute to the Molecular Diagnostics market growth in these regions. DelveInsight''s Molecular Diagnostics Market Insights and Forecast report provides the current and forecast Molecular Diagnostics Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Molecular Diagnostics Market.

This weekend's Barron's cover story says there will be a dramatic increase in betting on this year's Super Bowl, a trend that's likely to continue for years to come. Other featured articles discuss a

This weekend''s Barron''s cover story says there will be a dramatic increase in betting on this year''s Super Bowl, a trend that''s likely to continue for years to come. Other featured articles discuss a sign of hope for an online real-estate marketplace and why investors are pleased with the earnings of a beverage giant. Also, a gene-sequencing leader shows strong results and why Spotify may be underestimating the gravity of the Joe Rogan controversy. " The $22 Billion Wager: DraftKings and Others Are Reaching for a Piece of the Sports-Gambling Prize ," by Avi Salzman says bookmakers have always been busy on Super Bowl Sunday, but this year will be a bonanza like never before. Bettors are on track to wager $7.6 billion on the game, up 78% from last year. In " Zillow Stock Soars on Strong Results. The Company Says Exiting the Homebuying Business Was the Right Call ," Eric Savitz writes that Zillow Group Inc (NASDAQ: Z ) stock spiked this week after Full story available on Benzinga.com

Analysts have provided the following ratings for Illumina (NASDAQ:ILMN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 4 1 0 Last 3